(Columbia University Medical Center) Blacks and Hispanics have a significantly higher risk of developing precancerous colorectal polyps compared with whites, according to a study by researchers at NewYork - Presbyterian Hospital/Columbia University Medical Center. The findings appeared in the online edition of Alimentary Pharmacology and Therapeutics.

A study, published in the April 9 issue of Archives of Internal Medicine, reveals that patients are less likely to undergo colorectal cancer screening if their physicians only recommend a colonoscopy, compared with patients who are advised to undergo fecal occult blood testing (FOBT), or patients who are given the ...

When combined with other treatments, the drug cetuximab - which works by slowing or stopping the growth of cancer cells - has been shown to extend survival in certain types of cancer, including metastatic colorectal cancers. Unfortunately, about 40 percent of colorectal cancer patients - specifically those who carry a ...

Research on an investigational DNA methylation test for colorectal cancer demonstrated that the only clinical variable that influenced test results was age, according to results presented at the AACR Annual Meeting 2012, March 31 - April 4. "There was a progressive increase in background methylation levels that varied widely between ...

CHICAGO, IL (April 4, 2012)When combined with other treatments, the drug cetuximabwhich works by slowing or stopping the growth of cancer cellshas been shown to extend survival in certain types of cancer, including metastatic colorectal cancers. Unfortunately, about 40 percent of colorectal cancer patientsspecifically those who carry a mutated ...

Keryx Biopharmaceuticals, Inc. reported today that the Phase 3 "X-PECT" clinical trial evaluating perifosine (KRX-0401) + capecitabine (Xeloda) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo.

(American Association for Cancer Research) Patients did not have to adjust lifestyle or common drugs for this test. Age affected four methylation markers studied, but to different extents. Selecting optimal methylation markers may minimize false positives.

A study by University of Kentucky researchers showed that in Appalachia, colorectal cancer screening rates were higher in the population with multiple morbidities or diseases compared to those who had no morbidities at all. Published in the Southern Medical Journal, the study used data based on a survey of 1,153 ...

A study by University of Kentucky researchers showed that in Appalachia, colorectal cancer screening rates were higher in the population with multiple morbidities or diseases compared to those who had no morbidities at all.

LEXINGTON, Ky. -- A study by University of Kentucky researchers showed that in Appalachia, colorectal cancer screening rates were higher in the population with multiple morbidities or diseases compared to those who had no morbidities at all. Published in the Southern Medical Journal , the study ...

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 1/2 clinical trial of JX-594 in patients with metastatic colorectal cancer who have become refractory to chemotherapy ...

(University of Kentucky) A study by University of Kentucky researchers showed that in Appalachia, colorectal cancer screening rates were higher in the population with multiple morbidities or diseases compared to those who had no morbidities at all.